Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer by Wenners, Antonia Sophie et al.
Neutrophil Gelatinase-Associated Lipocalin (NGAL)
Predicts Response to Neoadjuvant Chemotherapy and
Clinical Outcome in Primary Human Breast Cancer
Antonia Sophie Wenners
1*, Keyur Mehta
2, Sibylle Loibl
2, Hyerim Park
1, Berit Mueller
5, Norbert Arnold
1,
Sigrid Hamann
1, Joerg Weimer
1, Beyhan Ataseven
3, Silvia Darb-Esfahani
5, Christian Schem
1,
Christoph Mundhenke
1, Fariba Khandan
4, Christoph Thomssen
6, Walter Jonat
1, Hans-
Juergen Holzhausen
7, Gunther von Minckwitz
2, Carsten Denkert
5, Maret Bauer
1
1Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Kiel, Germany, 2German Breast Group, GBG ForschungsGmbH, Neu-Isenburg,
Germany, 3Department of Obstetrics and Gynaecology, Rot-Kreuz-Klinikum Muenchen, Munich, Germany, 4St. Markus Hospital, Frankfurt am Main, Germany,
5Translational Tumorpathology Unit, Institute of Pathology, Charite ´, Berlin, Germany, 6Department of Gynecology, Martin-Luther-University of Halle-Wittenberg, Halle,
Germany, 7Department of Pathology, Martin Luther University of Halle–Wittenberg, Halle, Germany
Abstract
In our previous work we showed that NGAL, a protein involved in the regulation of proliferation and differentiation, is
overexpressed in human breast cancer (BC) and predicts poor prognosis. In neoadjuvant chemotherapy (NACT) pathological
complete response (pCR) is a predictor for outcome. The aim of this study was to evaluate NGAL as a predictor of response
to NACT and to validate NGAL as a prognostic factor for clinical outcome in patients with primary BC.
Immunohistochemistry was performed on tissue microarrays from 652 core biopsies from BC patients, who underwent
NACT in the GeparTrio trial. NGAL expression and intensity was evaluated separately. NGAL was detected in 42.2% of the
breast carcinomas in the cytoplasm. NGAL expression correlated with negative hormone receptor (HR) status, but not with
other baseline parameters. NGAL expression did not correlate with pCR in the full population, however, NGAL expression
and staining intensity were significantly associated with higher pCR rates in patients with positive HR status. In addition,
strong NGAL expression correlated with higher pCR rates in node negative patients, patients with histological grade 1 or 2
tumors and a tumor size ,40 mm. In univariate survival analysis, positive NGAL expression and strong staining intensity
correlated with decreased disease-free survival (DFS) in the entire cohort and different subgroups, including HR positive
patients. Similar correlations were found for intense staining and decreased overall survival (OS). In multivariate analysis,
NGAL expression remained an independent prognostic factor for DFS. The results show that in low-risk subgroups, NGAL
was found to be a predictive marker for pCR after NACT. Furthermore, NGAL could be validated as an independent
prognostic factor for decreased DFS in primary human BC.
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Introduction
Human neutrophil gelatinase-associated lipocalin (NGAL or
lipocalin 2) is a small 25 kDa extracellular protein, expressed by
neutrophils and originally presenting itself in complex with
neutrophil gelatinase, also known as matrix metalloproteinase 9
(MMP-9) [1]. NGAL belongs to the lipocalin protein family, which
has been classified as transport proteins of lipophilic molecules. As
an acute phase protein, NGAL additionally plays a role in
inflammatory conditions and immune response, including the
synthesis of prostaglandins [2]. It has also been observed that
NGAL actively participates in the process of proliferation,
developement and differentiation of different human tissues
[3,4]. Thus, NGAL plays an important role in the pathophysiology
of neoplasias. Regarding different tumor entities, contradicting
results about its involvement in tumor developement were shown.
Whereas NGAL seems to have a pro-tumoral effect in breast [5,6],
stomach [7,8], oesophagus [9], kidney [10] and thyroid cancer
[11], its influence on ovary [12] and pancreas [13] appears to be
rather anti-tumoral. For colorectal cancer results are controversial
[14,15,16]. These findings suggest a neoplasia-specific effect of
NGAL. Stoesz et al. [17] observed that NGAL was overexpressed
in breast cancer. Based on these findings, we showed in our
previous work that in breast cancer NGAL expression is correlated
with negative hormone receptor (HR) status, human epidermal
growth factor receptor 2 (HER2) overexpression, poor grading
and positive nodal status. NGAL expression was associated with
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e45826shorter disease-specific and disease-free survival and was proven to
be an independent prognostic marker for disease-free survival [5].
Neoadjuvant chemotherapy (NACT) is used for treatment of
locally advanced breast cancer since the 1970s in order to
downsize large tumors to enable breast-conserving surgery [18].
Lately, NACT is increasingly being used for treatment of early-
stage breast cancer as well [19]. NACT reaches at least equivalent
disease-free survival (DFS) and overall survival (OS) rates
compared to adjuvant chemotherapy, presumably through early
treatment of systemic micrometastatic disease [18,20]. An
advantage of NACT is that it gives information about tumor
response to a specific chemotherapeutic regimen and therefore
allows biologic studies to investigate molecular determinants of
chemotherapy response. It was shown that tumor response to
preoperative chemotherapy correlates with outcome. Pathological
complete response (pCR) seems to be the most powerful predictor
of response and survival [21]. 3–30% of patients achieve pCR
after NACT and have improved outcome (DFS and OS)
compared to patients with residual disease at the primary tumor
site or lymph nodes [22,23]. Despite high response rates of 60–
90% to NACT [20], a small population fails to respond or show
progressive disease and therefore features poor prognosis. [24].
Early identification of these non-responders is an urgent goal to
enable alternative treatment choices. There are already several
predictive biological markers such as negative steroid receptor
status, high histopathological grading, high Ki67-proliferation
index [25], small tumor size [26] and tumor type of invasive ductal
carcinoma (IDC) [27]. Lately, four subgroups of breast cancer
have been identified based on gene expression profiles (luminal A
and B, basal-like and HER2 positive) [28]. Even if detection of
predictive markers strongly depends on the drugs used in NACT
[29,30], one of the largest studies on gene expression showed that
specific gene expression profiles are valid independent variables
predicting pathological complete response [31]. Therefore, it
should be ultimated ambition to find more reliable markers that
can predict clinical or pathological response in early stage of
treatment. NACT allows clinical monitoring of in vivo tumor
responses and therefore presents an interesting model to evaluate
new biological markers [25]. Information about such markers
could help to perform an individual and optimal treatment
concept for each patient, a so called ‘‘tailored therapy’’.
NGAL could be one of those potential biomarkers to forecast
response to NACT. Hence, based on our previous work we aim to
not only validate NGAL as a predictor of prognosis in breast
cancer, but also to evaluate NGAL as a potential predictive
marker in neoadjuvant chemotherapy.
Materials and Methods
Specimens and clinical information were provided by the
neoadjuvant GeparTrio study, a prospective, multicentre, ran-
domized phase III trial, that investigated a total of 2090 patients
with operable primary breast carcinoma (cT2-4, cN0-3, M0)
between July 2001 and December 2005 [32,33,34]. Ethics
approval for the study was obtained from the ethics committee
of each participating institution. All patients gave their written
informed consent for participation in the study and for tumor
tissue sampling. The trial registration number (clinicaltrials.gov) is
NCT 00544765 [32,33]. Primary endpoint of the GeparTrio trial
was to evaluate pCR after neoadjuvant cytotoxic therapy with six
to eight cycles docetaxel, doxorubicin, cyclophosphamide (TAC)
or two cycles of TAC followed by four cycles of vinorelbine and
capecitabine, depending on response status [33]. pCR for this
analysis was defined as no residual invasive tumor cells from the
breast and axillary tissue (ypT0/ypTis, ypN0). A total of 855
breast cancer cases with corresponding clinical and histopatho-
logical data, such as analyses of estrogen receptor (ER),
progesterone receptor (PR) and HER2 status, histological grading
and subtype, lymph node status and tumorsize, were available for
this study. All data, including clinical and pathological response, as
Figure 1. NGAL expression in human breast cancer tissues. (A) Negative NGAL staining (staining intensity score 0). (B) Weak NGAL staining
(staining intensity score 1). (C) Moderate NGAL staining (staining intensity 2). (D) Strong NGAL staining (staining intensity 3). Original magnification:
4006.
doi:10.1371/journal.pone.0045826.g001
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(GBG). The median follow up time was 59 months with a range
between 2 months and 96 months. The median age was 51 years,
ranging from 24 to 78 years.
Pathologic assessment
Tissue microarrays of formalin-fixed, paraffin-embedded pre-
therapeutic core biopsies were constructed by the Institute of
Pathology, Charite ´ University Hospital, Berlin, Germany. Immu-
nohistochemical staining was performed by Discovery XT staining
system (Ventana Medical Systems, Tuscon, USA). After epitope
retrieval, primary anti-NGAL antibody was added in a dilution of
1:120. The generation of this rabbit polyclonal anti-NGAL
antibody has been reported by Stoesz et al. [17]. After incubation
with the secondary polyclonal goat anti-rabbit antibody in a
dilution of 1:200 (DAKO, Denmark A/S) antibody labelling was
visualized using the ABC vector stain kit (Vector laboratories,
Burlingame, CA). NGAL was evaluated by expression (negative vs
positive) and intensity of staining. The intensity score ranged from
0 (no staining), 1 (=weak), 2 (=intermediate) to 3 (=strong)
staining (Figure 1) [35]. Scoring of all slides was done by two
independent investigators (H.P. and M.B.).
Statistical analyses
The primary clinical endpoints were pCR, disease-free survival
and overall survival. Survival was calculated in months from the
date of diagnosis until the date of first relapse (DFS) or death (OS)
for each patient. Both DFS and OS time were censored at the date
of last follow-up if no recurrence, respectively death was observed.
Patient characteristics were summarized by standard descriptive
statistics. The associations between NGAL expression and
clinicopathologic variabels as well as associations with pCR in
various subgroups were assessed by cross-tabulation, x
2-test and
Fisher’s exact test. Cox proportional hazard models were used to
perform uni- and multivariate analysis and to determine the
prognostic significance of the reviewed variables, including NGAL
expression, for being predictive markers for pCR, DFS and OS.
DFS and OS survival probabilities were estimated using the
Kaplan-Meier product limit method. Log rank tests were used to
calculate the survival functions. No correction for multiple testing
was performed. P-values#0.05 were considered as statistically
significant. For statistical analysis of data, the Software packages
SPSS 14.0 and SAS 9.2 were used. All tests were two-sided.
Table 1. Association between NGAL-expression and clinicopathologic variables.
Variable NGAL expression (%) p-value NGAL staining intensity (%) p-value
positive negative 0 1 2 3
Hormone receptor status (n=639)
positive (n=487) 71.9 79.3 0.038 79.2 76.1 73.3 53.5 0.002
negative (n=152) 28.1 20.7 20.8 23.9 26.7 46.5
Estrogen receptor status (n=640)
positive (n=487) 71.6 79.3 0.031 79.2 75.6 73.3 53.5 0.002
negative (n=153) 28.4 20.7 20.8 24.4 26.7 46.5
Progesterone receptor status (n=619)
positive (n=343) 50.6 58.8 0.049 58.7 57.4 46.6 30.2 0.002
negative (n=276) 49.4 41.2 41.3 42.6 53.4 69.8
HER2 status (n=640)
positive (n=135) 21.1 21.1 1.0 21.1 21.0 19.0 22.7 0.973
negative (n=505) 78.9 78.9 78.9 79.0 81.0 77.3
Histological grade (n=650)
1/2 (n=491) 74.1 76.6 0.462 76.5 79.3 65.6 65.9 0.073
3 (n=159) 25.9 23.4 23.5 20.7 34.4 34.1
Tumor type (n=651)
ductal and other (n=605) 96.0 90.7 0.009 90.7 96.4 93.4 97.7 0.054
lobular (n=46) 4.0 9.3 9.3 3.6 6.6 2.3
Lymph node status (n=630)
positive (n=346) 56.3 53.9 0.572 53.9 54.3 60.7 59.1 0.729
negative (n=284) 43.7 46.1 46.1 45.7 39.3 40.9
Tumor size [mm] (n=637)
,40 (n=261) 39.3 42.2 0.515 42.3 39.8 37.7 40.9 0.889
$40 (n=376) 60.7 57.8 57.7 60.2 62.3 59.1
Age [years] (n=642)
,50 (n=297) 44.0 48.0 0.337 47.8 41.9 49.1 45.5 0.604
$50 (n=345) 56.0 52.0 52.2 58.1 50.8 54.5
Abbreviations: NGAL, Neutrophil gelatinase-associated lipocalin; HER2, human epidermal growth factor receptor 2.
doi:10.1371/journal.pone.0045826.t001
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Variable NGAL expression (%) p-value NGAL staining intensity (%) p-value
positive negative 0 1 2 3
Entire cohort (n=642) pCR 22.7 19.8 0.379 19.8 21.6 19.7 31.8 0.323
no pCR 77.3 80.2 80.2 78.4 80.3 68.2
Hormone receptor status (n=639)
positive (n=487) pCR 18.4 11.3 0.033 11.4 14.8 20.5 34.8 0.010
no pCR 81.6 88.7 88.6 85.2 79.5 65.2
negative (n=152) pCR 30.7 51.4 0.013 51.4 41.0 12.5 25.0 0.013
no pCR 69.3 48.6 48.6 59.0 87.5 75.0
Estrogen receptor status (n=640)
positive (n=487) pCR 18.4 11.3 0.033 11.4 14.8 20.5 34.8 0.010
no pCR 81.6 88.7 88.6 85.2 79.5 65.2
negative (n=153) pCR 30.3 51.4 0.012 51.4 40.0 12.5 25.0 0.013
no pCR 69.7 48.9 48.6 60.0 87.5 75.0
Progesterone receptor status (n=619)
positive (n=343) pCR 10.8 10.8 1.0 10.8 9.0 11.1 23.1 0.507
no pCR 89.2 89.2 89.2 91.0 88.9 76.9
negative (n=276) pCR 32.3 32.2 1.0 32.2 36.4 22.6 33.3 0.603
no pCR 67.7 67.8 67.8 63.6 77.4 66.7
HER2 status (n=640)
positive (n=135) pCR 36.8 28.9 0.355 28.9 40.0 27.3 40.0 0.631
no pCR 63.2 71.1 71.1 60.0 72.7 60.0
negative (n=505) pCR 18.9 17.1 0.637 17.1 16.8 17.0 29.4 0.345
no pCR 81.1 82.9 82.9 83.2 83.0 70.6
Histological grade (n=650)
1/2 (n=491) pCR 19.9 16.3 0.335 16.4 16.7 17.5 37.9 0.036
no pCR 80.1 83.7 83.6 83.3 82.5 62.1
3 (n=159) pCR 31.0 31.0 1.0 31.0 40.0 23.8 20.0 0.443
no pCR 69.0 69.0 69.0 60.0 76.2 80.0
Tumor type (n=651)
ductal and other (n=605) pCR 23.7 21.3 0.490 21.3 22.4 21.1 32.6 0.418
no pCR 76.3 78.7 78.7 77.6 78.9 67.4
lobular (n=46) pCR 0.0 5.7 1.0 5.7 0.0 0.0 0.0 0.883
no pCR 100.0 94.3 94.3 100.0 100.0 100.0
Lymph node status (n=630)
positive (n=346) pCR 19.7 20.1 1.0 20.1 20.2 18.9 19.2 0.998
no pCR 80.3 79.9 79.9 79.8 81.1 80.8
negative (n=284) pCR 27.1 19.9 0.156 19.9 24.0 20.8 50.0 0.038
no pCR 72.9 80.1 80.1 76.0 79.2 50.0
Tumor size [mm] (n=637)
,40 (n=261) pCR 25.5 21.1 0.452 21.1 22.7 13.6 50.0 0.031
no pCR 74.5 78.9 78.9 77.3 86.4 50.0
$40 (n=376) pCR 20.0 18.0 0.691 18.1 20.0 21.1 19.2 0.963
no pCR 80.0 82.0 81.9 80.0 78.9 80.0
Age [years] (n=642)
,50 (n=297) pCR 31.7 24.3 0.185 24.4 31.4 26.7 40.0 0.398
no pCR 68.3 75.7 75.6 68.6 73.3 60.0
$50 (n=345) pCR 15.7 15.6 1.0 15.6 14.4 12.9 25.0 0.600
no pCR 84.3 84.4 84.4 85.6 87.1 75.0
Abbreviations: NGAL, Neutrophil gelatinase-associated lipocalin; pCR, pathologic complete response; HER2, human epidermal growth factor receptor 2.
doi:10.1371/journal.pone.0045826.t002
NGAL in Primary Human Breast Cancer
PLOS ONE | www.plosone.org 4 October 2012 | Volume 7 | Issue 10 | e45826Table 3. Univariate Cox Survival Analysis for NGAL expression.
Variable
NGAL
expression Disease-free survival Overall survival
E/N
Hazard
ratio
95% confidence
interval p-value E/N
Hazard
ratio
95% confidence
interval p-value
Entire cohort positive 73/273 1.00 1.294–2.556 ,0.001 37/273 1.00 0.881–2.161 0.159
negative 61/369 1.82 40/369 1.38
pCR
yes positive 7/62 1.00 0.316–2.103 0.673 4/62 1.00 0.234–2.936 0.771
negative 11/73 0.82 6/73 0.83
no positive 66/211 1.00 1.464–3.059 ,0.001 33/211 1.00 0.933–2.440 0.093
negative 50/296 2.12 34/296 1.51
Hormone receptor status
positive positive 47/190 1.00 1.262–2.892 0.002 24/190 1.00 0.846–2.526 0.174
negative 43/291 1.91 28/291 1.46
negative positive 23/78 1.00 0.732–2.568 0.324 12/75 1.00 0.456–2.261 0.971
negative 17/74 1.37 12/74 1.02
Estrogen receptor status
positive positive 47/190 1.00 1.262–2.892 0.002 24/190 1.00 0.846–2.526 0.174
negative 43/291 1.91 28/291 1.46
negative positive 24/76 1.00 0.760–2.637 0.273 12/76 1.00 0.448–2.221 0.995
negative 17/74 1.42 12/74 0.99
Progesterone receptor status
positive positive 33/130 1.00 1.282–3.501 0.003 15/130 1.00 0.734–2.858 0.285
negative 29/213 2.12 19/213 1.45
negative positive 38/127 1.00 1.028–2.705 0.038 21/127 1.00 0.682–2.323 0.462
negative 29/146 1.67 21/146 1.26
HER2 status
positive positive 20/57 1.00 0.850–3.105 0.142 8/57 1.00 0.400–2.475 0.990
negative 17/76 1.63 12/76 0.99
negative positive 53/212 1.00 1.285–2.879 0.001 29/212 1.00 0.964–2.757 0.068
negative 43/285 1.92 27/287 1.63
Histological grade
1a n d2 positive 51/201 1.00 1.345–3.085 ,0.001 27/201 1.00 0.907–2.649 0.109
negative 40/282 2.04 27/282 1.55
3 positive 22/71 1.00 0.711–2.388 0.392 10/71 1.00 0.440–2.291 0.993
negative 21/77 1.30 13/87 1.00
Tumor type
ductal and other positive 71/262 1.00 1.268–2.548 0.001 35/262 1.00 0.869–2.210 0.171
negative 57/334 1.80 36/334 1.39
lobular positive 2/11 1.00 0.272–8.241 0.643 2/11 1.00 0.328–11.798 0.458
negative 4/35 1.50 4/35 1.97
Lymph node status
positive positive 53/152 1.00 1.355–3.163 ,0.001 28/152 1.00 0.840–2.446 0.186
negative 36/194 2.07 26/194 1.43
negative positive 20/118 1.00 0.771–2.562 0.266 9/118 1.00 0.490–2.769 0.729
negative 23/166 1.41 12/166 1.17
Tumor size [mm]
,40 positive 22/106 1.00 1.019–3.374 0.043 15/106 1.00 1.090–5.170 0.029
negative 21/154 1.85 12/152 2.37
$40 positive 51/165 1.00 1.199–2.782 0.005 22/165 1.00 0.563–1.741 0.971
negative 38/211 1.83 27/211 0.99
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NGAL expression in breast carcinoma cells
Pretreatment breast cancer biopsies from 855 participants of the
GeparTrio trial were evaluated for NGAL expression. Due to loss
of tumor tissue during tissue microarray construction, NGAL
labelling was interpretable in 651 breast cancer samples. In 42.2%
(n=275) of the breast cancer patients NGAL detection was
positive. Positive immunoreactivity was predominantly detected in
the cytoplasm, but a subset of carcinomas showed secretion of
NGAL in the duct lumens. NGAL staining intensity varied from
negative to strong staining (Figure 1). 375 (57.7%) tumors
presented negative staining, 169 (26.1%) showed a weak intensity.
Medium intensity was expressed by 61 (9.4%) patients and 44
(6.8%) patients had strong staining intensity. The distribution
pattern of NGAL labelling was comparable to our previous
findings and varied from a weak staining of all tumor cells to a
strong focal labelling [5]. 12 patients (1.8%) showed strong NGAL
expression in all tumor cells. Remarkably, only 4% (n=11) of the
NGAL positive tumors were lobular carcinomas, whereas 96%
(n=264) showed ductal or other histological subtypes.
Association between NGAL expression and
clinicopathologic parameters
NGAL expression in breast carcinoma cells was significantly
associated with histological tumor type, hormone receptor (HR)
status, estrogen receptor (ER) and progesterone receptor (PR)
status.
Positive NGAL labelling was significantly associated with the
ductal or other histological subtypes (p=0.009). Positive NGAL
expression and strong staining intensity (3) were correlated with
steroid receptor status. Negative receptor status was significantly
more prevalent in NGAL positive tumors than in NGAL negative
tumors (Table 1). The proportion of tumors with negative
hormone receptor status was also higher in tumors with an NGAL
intensity score of 3 compared to tumors with intensity scores of 2,
1 or 0 (Table 1). No significant correlations were found between
NGAL expression or intensity and HER2 status, nodal status,
histological grade, tumor size and age (Table 1).
Association between NGAL expression and pCR
Overall pCR rate was 21% in the entire cohort. pCR rate in
NGAL negative patients was 19.8% and pCR rate in NGAL
positive patients 22.7%. If we use the staining intensity, the group
with strong NGAL staining had a pCR rate of 31.8% compared to
19.7% in the group with moderate staining and 21.6% in patients
with weak NGAL staining intensity. NGAL expression was
significantly associated with higher pCR rates in patients with
positive hormone receptor status (p=0.033). In patients with
hormone receptor positive tumors the pCR rate in NGAL positive
tumors was 18.4% vs. 11.3% in NGAL negative tumours. NGAL
was shown to be a marker for lower pCR rates in hormone
receptor negative patients (30.7% vs. 51.4%, p=0.013). Accor-
dant results have been shown for patients with positive and
negative estrogen receptor status (Table 2). In the categories PR
status, HER2 status, histological grade, lymph node status, tumor
type and size as well as age no association between NGAL
expression and pCR rate was detected.
NGAL staining intensity was shown to be a marker for higher
pCR rates in several subgroups of known low risk, such as estrogen
and progesterone positive and lymph node negative patients,
patients with histological grade 1 or 2 tumors and a tumor size
,40 mm (Table 2). In the HR and ER positive subgroups higher
pCR rates were detected in tumors with a NGAL intensity score of
3 compared to tumors with lower intensity scores of 2, 1 or 0
34.8% vs. 20.5% vs. 14.8% vs. 11.4%, p=0.01). Furthermore, the
subgroup of lymph node negative patients presented higher pCR
rates in tumors with strongest NGAL intensity (50.0% vs. 20.8%
vs. 24.0% vs. 19.9%, p=0.038). Within the group of patients with
favourable grading the proportion of tumors with higher pCR
rates was higher in tumors showing strongest NGAL staining than
in those with less staining intensity (37.9% vs. 17.5% vs. 16.7% vs.
16.4%, p=0.036). Finally, regarding the group of tumors with a
size ,40 mm, higher pCR rates were found in the intensity 3
tumors compared to tumors with a staining intensity of 2, 1 or 0
(50.0% vs. 13.6% vs. 22.7% vs. 21.1%, p=0.031). In addition,
strong NGAL staining intensity was associated with higher pCR
rates in further groups of low-risk such as PR positive and HER2
negative tumors, tumors of ductal type and in patients younger
than 50 years of age. However, these results did not reach
significance.
Multivariate cox regression analysis revealed age, HR and
HER2 status as independent predictors of pCR. NGAL failed to
be an independent predictor of pCR in the entire study cohort
(data not shown).
Association between NGAL expression and disease-free
survival
In univariate survival analysis, positive NGAL expression and
strong NGAL staining intensity in breast carcinoma cells were
highly significantly associated with decreased DFS in the entire
cohort (NGAL expression: HR=1.82, p,0.001; NGAL intensity:
Table 3. Cont.
Variable
NGAL
expression Disease-free survival Overall survival
E/N
Hazard
ratio
95% confidence
interval p-value E/N
Hazard
ratio
95% confidence
interval p-value
Age [years]
,50 positive 29/120 1.00 0.865–2.382 0.162 16/120 1.00 0.650–2.464 0.488
negative 31/177 1.44 19/177 1.27
$50 positive 44/153 1.00 1.399–3.552 ,0.001 21/153 1.00 0.862–3.000 0.136
negative 30/192 2.23 21/192 1.61
Abbreviations: NGAL, Neutrophil gelatinase-associated lipocalin; pCR, pathologic complete response; HER2, human epidermal growth factor receptor 2; E, number of
events; N, total sample size.
doi:10.1371/journal.pone.0045826.t003
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group. NGAL negative patients showed a mean DFS of 81.5
months, whereas the NGAL positive group had a mean DFS of
67.0 months.
Stratification into different subgroups revealed a significant
association between NGAL expression and DFS in multiple
groups. Decreased DFS in NGAL expressing tumors was found in
patients who fail to respond to NACT with pCR (HR=2.12,
p,0.001), in patients with positive HR and ER status (HR=1.91,
p=0.002) and both positive and negative PR expressing patients
(PR positive: HR=2.12, p=0.003; PR negative: HR=1.67,
p=0.038). Similar results were achieved for HER2 negative
tumors (HR=1.92, p=0.001), lymph node positive tumors
(HR=2.07, p,0.001), grade 1 and 2 tumors (HR=2.04,
p,0.001), the ductal subtype (HR=1.8, p=0.001), a tumor size
,40 mm (HR=1.85, p=0.043) as well as $40 mm (HR=1.83,
p=0.005) and patients older than 50 years (HR=2.23, p,0.001)
(Table 3).
In these subgroups consistent results were observed for strong
NGAL staining intensity. Tumors that feature a NGAL intensity of
2 or 3 were significantly associated with shorter DFS than tumors
with a NGAL intensity 0 or 1 (Table 4). The only groups that have
to be added to the list above are patients with an unfavourable
grading (G3; HR=2.12, p=0.003) and negative lymph node
status (HR=2.34, p=0.02), they also show decreased DFS when
having a strong NGAL staining intensity (Figure 2 A–F).
Figure 2. Long-term outcome of patients depending on NGAL expression and intensity in months. (A) DFS in all patients by NGAL
expression neg. vs. pos. (B) DFS in all patients by NGAL intensity 0–1 vs. 2–3. (C) DFS in HR positive patients by NGAL expression neg. vs. pos. (D) DFS
in HR positive patients by NGAL intensity 0–1 vs. 2–3. (E) DFS in patients without pCR by NGAL expression neg. vs. pos. (F) OS in patients without pCR
by NGAL intensity 0–1 vs. 2–3. NGAL: neutrophil gelatinase-associated lipocalin. DFS: disease-free survival. OS: overall survival. HR: hormone.
doi:10.1371/journal.pone.0045826.g002
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Variable
NGAL
staining
intensity Disease-free survival Overall survival
E/N
Hazard
ratio
95% confidence
interval p-value E/N
Hazard
ratio
95% confidence
interval p-value
Entire cohort 0 and 1 100/535 1.00 1.462–3.192 ,0.001 60/535 1.00 0.984–2.898 0.057
2 and 3 34/105 2.16 17/105 1.69
pCR
yes 0 and 1 15/109 1.00 0.291–3.476 0.992 8/109 1.00 0.255–5.664 0.816
2 and 3 3/26 1.01 2/26 1.20
no 0 and 1 85/426 1.00 1.669–3.815 ,0.001 52/426 1.00 1.021–3.234 0.042
2 and 3 31/79 2.52 15/79 1.82
Hormone receptor status
positive 0 and 1 69/412 1.00 1.379–3.672 0.001 41/412 1.00 0.949–3.615 0.071
2 and 3 21/67 2.25 11/67 1.85
negative 0 and 1 27/113 1.00 0.995–3.778 0.0516 18/113 1.00 0.494–3.145 0.6408
2 and 3 13/36 1.934 6/36 1.25
Estrogen receptor status
positive 0 and 1 69/412 1.00 1.379–3.672 0.0012 41/412 1.00 0.949–3.615 0.0706
2 and 3 21/67 2.25 11/67 1.85
negative 0 and 1 28/114 1.00 0.978–3.681 0.0583 18/114 1.00 0.500–3.181 0.6238
2 and 3 13/36 1.90 6/36 1.26
Progesterone receptor status
positive 0 and 1 48/301 1.00 1.461–4.824 0.0014 26/301 1.00 1.249–6.154 0.0122
2 and 3 14/40 2.66 8/40 2.77
negative 0 and 1 47/212 1.00 1.087–3.111 0.0231 33/212 1.00 0.531–2.336 0.7764
2 and 3 20/61 1.84 9/61 1.11
HER2 status
positive 0 and 1 29/111 1.00 0.740–3.566 0.220 17/111 1.00 0.269–3.208 0.906
2 and 3 8/21 1.62 3/21 0.93
negative 0 and 1 70/417 1.00 1.541–3.803 ,0.001 42/417 1.00 1.141–3.847 0.017
2 and 3 26/81 2.42 14/81 2.10
Histological grade
1a n d2 0 and 1 70/413 1.000 1.292–3.433 0.003 45/413 1.00 0.644–2.703 0.449
2 and 3 21/69 2.12 9/69 1.32
3 0 and 1 30/122 1.00 1.052–3.917 0.035 15/122 1.00 0.932–5.208 0.072
2 and 3 13/36 2.03 8/36 2.20
Tumor type
ductal and other 0 and 1 95/494 1.00 1.461–3.234 ,0.001 56/494 1.00 0.887–2.781 0.121
2 and 3 33/100 2.17 15/100 1.57
lobular 0 and 1 5/41 1.00 0.188–14.063 0.659 4/41 1.00 0.834–30.048 0.078
2 and 3 1/5 1.62 2/5 5.01
Lymph node status
positive 0 and 1 65/283 1.00 1.220–3.115 0.005 42/283 1.00 0.752–2.715 0.276
2 and 3 24/63 1.95 12/63 1.43
negative 0 and 1 33/241 1.00 1.145–4.772 0.020 16/241 1.00 0.727–5.490 0.1796
2 and 3 10/42 2.34 5/42 1.99
Tumor size [mm]
,40 0 and 1 32/218 1.00 1.413–5.613 0.003 21/218 1.00 0.881–5.482 0.091
2 and 3 11/40 2.82 6/40 2.20
$40 0 and 1 66/310 1.00 1.168–3.024 0.009 38/310 1.00 0.695–2.680 0.366
2 and 3 23/64 1.88 11/64 1.37
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survival
A statistically significant association between decreased OS and
positive NGAL expression was shown in patients with a tumor size
,40 mm (HR=2.37, p=0.029) in univariate cox survival analysis
(Table 3). Patients with strong NGAL staining intensity (2 or 3)
had a significantly decreased OS compared to tumors with NGAL
staining 0 or 1 if they fail to reach pCR (HR=1.82, p=0.042;
Figure 2 E). The same applied on patients in the PR positive
(HR=2.77, p=0.012) and in the HER2 negative subgroup
(HR=2.1, p=0.017; Table 4).
Multivariate survival analysis
Known independent markers for decreased DFS and OS could
be confirmed in multivariate cox proportional hazard analysis
(Table 5 and 6). DFS was independently marked by pCR
(HR=0.4, p,0.001), hormone receptor status (HR=0.64,
p=0.038) and nodal status (HR=1.69, p=0.007), HER2 status
(HR=0.66, p=0.038) and histological grade (HR=1.62,
p=0.021) (Table 5). The following variables were identified as
independent prognostic markers for OS: pCR (HR=0.41,
p=0.015), hormone receptor status (HR=0.56, p=0.04) and
nodal status (HR=2.21, p=0.003). Positive NGAL expression
(HR=1.76; p=0.002) and strong NGAL intensity (HR=2.05;
p=0.004) were independently prognostic for decreased DFS in
multivariate analysis. For OS, NGAL expression and intensity
failed to be identified as independent prognostic factors (Table 6).
Discussion
In this study we could evaluate NGAL as a potentially predictive
marker for response to NACT in low-risk groups of primary
human breast cancer and validate NGAL as a predictor of poor
prognosis in this entity. NGAL expression was positive in 42.2% of
all cases. This number lies within the range of previous reports
[5,17,36].
Our findings show an association between NGAL expression
and negative hormone receptor status (ER and PR). This confirms
the results of our previous work [5] and is also consistent with the
statements of other studies, that examined gene expression
profiling of breast carcinomas [37,38]. Negative hormone receptor
status is known to be a parameter for more aggressive tumors,
which are characterized by showing better response to NACT,
more often achieving pathological complete response [39,40]. Like
negative hormone receptor status there exist several high-risk
Table 4. Cont.
Variable
NGAL
staining
intensity Disease-free survival Overall survival
E/N
Hazard
ratio
95% confidence
interval p-value E/N
Hazard
ratio
95% confidence
interval p-value
Age [years]
,50 0 and 1 46/246 1.00 0.926–3.067 0.087 26/246 1.00 0.839–3.836 0.131
2 and 3 14/50 1.69 9/50 1.79
$50 0 and 1 54/289 1.00 1.590–4.474 ,0.001 34/289 1.00 0.763–3.604 0.202
2 and 3 20/55 2.67 8/55 1.66
Abbreviations: NGAL: Neutrophil gelatinase-associated lipocalin. pCR: pathologic complete response. HER: human epidermal growth factor receptor; E, number of
events; N, total sample size.
doi:10.1371/journal.pone.0045826.t004
Table 5. Multivariate Cox Survival Analysis - Disease-free
survival.
Variable
Hazard
ratio
95% confidence
interval p-value
NGAL expression
positive 1.76 1.230–2.522 0.002
negative
NGAL staining intensity
2 and 3 2.05 1.254–3.362 0.004
0 and 1
pCR
yes 0.40 0.234–0.682 ,0.001
no
Hormone receptor status
positive 0.64 0.418–0.975 0.038
negative
HER2 status
negative 0.66 0.442–0.977 0.038
positive
Histological grade
3 1.62 1.075–2.426 0.021
1 and 2
Tumor type
ductal/other 0.68 0.272–1.708 0.413
lobular
Lymph node status
positive 1.69 1.152–2.468 0.007
negative
Tumor size [mm]
$40 1.14 0.773–1.687 0.505
,40
Age [years]
$50 0.94 0.653–1.345 0.726
,50
doi:10.1371/journal.pone.0045826.t005
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biological markers predicting pCR in low-risk groups. The
question if patients with low-risk tumor characteristics would
benefit from an additional chemotherapy is often raised in daily
clinical routine. So far there are no instruments easy to access that
would help us in decision-making. One commercially avaible gene
expression test was introduced to evaluate patients’ individual risk
of relapse and response to chemotherapy, guiding the way for
introducing patients with a low-risk tumor profile to chemotherapy
or not. Drawbacks of the use of this testing module for clinical
routine are the effort of time and costs [41].
The present results reveal NGAL staining intensity as a marker
for higher pCR rates in subgroups of low risk. This applies on
hormone receptor positive and node negative patients, patients
with favourable histological grade and a tumor size ,40 mm. This
is a very interesting and useful finding, especially in the context
mentioned above. Nevertheless, it also has to be recognized that
NGAL did not show to be an independent predictor for pCR in
multivariate analysis.
In survival analysis, decreased DFS in patients whose tumors
showed positive NGAL expression was found in the entire cohort,
but also in different subgroups. Those were patients without pCR,
with positive HR and ER status, positive and negative PR
expressing tumors, HER2 negative and lymph node positive
tumors, grade 1 and 2 tumors, the ductal subtype, a tumor size
,40 mm as well as $40 mm and patients older than 50 years.
Decreased OS in NGAL expressing patients was only noted in
patients with a tumor smaller than 40 mm, respectively in patients
who failed to reach pCR or with HER2 negative or PR positive
tumors regarding NGAL intensity.
Inspite of the large sample size of tumors in this study, NGAL
failed to be an independent marker for OS, as it has also done
previously [5]. But NGAL expression and intensity were shown to
be independent predictors for DFS, which confirms our former
findings [5]. Thus, not only does NGAL expression present itself as
a predictor for response to chemotherapy in subgroups of low risk,
it also appears to be a marker for recurrence of disease. Therefore,
it is conceivable that NGAL might be a future marker for
individual therapeutic decisions to enable a tailored therapy for
each breast cancer patient. NGAL expression can be easily
determined by immunohistochemistry in daily routine. No
additional tissue sampling is necessary.
For a methodical point our results are based on reliable data
due to the homogeneous collective underlying the German
GeparTrio study. In this large study cohort each patient met the
same inclusion criteria and received identical chemotherapy
regime. However, it has to be borne in mind that validation of
predictive markers strongly depends on the drugs used in the
specific therapeutic setting [39].
The NGAL molecule plays an important role in cell biology and
interfears with different molecular pathways. Its functions can be
divided into pro-tumoral and anti-tumoral effects. For pro-tumoral
effect NGAL participates in the intracellular capture of iron [42].
Furthermore, NGAL assists tumor growth and angiogenesis by
forming complexes with MMP-9, thereby protecting MMP-9 from
degradation [43]. Additionally, NGAL plays a role in the
mechanisms of estrogen-induced growth. [42]. NGAL has an
anti-metastatic role by inhibiting HIF-1a factor, FA-Kinase
phosphorylation and also by retaining synthesis of vascular
endothelial growth factor (VEGF) [42].
In summary, NGAL was found to be a predictive marker for
pCR after NACT in low-risk subgroups. Furthermore, NGAL
could be validated as an independent prognostic factor for
decreased DFS in primary human breast cancer. To realise an
individualized targeted therapy for breast cancer patients further
knowledge and reliability concerning predictive markers for
chemotherapy are necessary. Nevertheless, NGAL appears to be
a very promising part on the way to achieve this goal.
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Table 6. Multivariate Cox Survival Analysis - Overall survival.
Variable
Hazard
ratio
95% confidence
interval p-value
NGAL expression
positive 1.35 0.842–2.159 0.213
negative
NGAL staining intensity
2a n d3 1.40 0.754–2.594 0.288
0a n d1
pCR
yes 0.41 0.198–0.843 0.015
no
Hormone receptor status
positive 0.56 0.323–0.973 0.040
negative
HER2 status
negative 0.79 0.463–1.337 0.376
positive
Histological grade
3 1.58 0.910–2.725 0.105
1a n d2
Tumor type
lobular 1.44 0.554–3.736 0.4549
ductal/other
Lymph node status
positive 2.21 1.310–3.737 0.003
negative
Tumor size [mm]
,40 0.99 0.604–1.654 0.998
$40
Age [years]
$50 0.91 0.569–1.463 0.703
,50
doi:10.1371/journal.pone.0045826.t006
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